Neurotrophic Keratopathy: Current Perspectives

AbstractPurpose of ReviewNeurotrophic keratopathy (NK) is a challenging ophthalmological disease. In this review, we present an updated evidence-based summary on the pathophysiology, classification, diagnosis, and how novel therapies have changed the management of NK.Recent FindingsNew specific medical and surgical modalities are emerging, such as Cenegermin (Oxervate ®, Dompé) and neurotization procedures, which are changing the paradigm of the treatment of NK. In addition, more diagnostic resources are available, such as corneal confocal microscopy in vivo, non-contact esthesiometers, and common ocular surface points of care test, which have been validated in this condition.SummaryNK is a disease produced by an impairment of corneal innervation caused by a variety of local and systemic disorders, such as viral infection, medicamentosa, chronic contact lens use, surgical or iatrogenic, diabetes, multiple sclerosis, and more, that leads to a progressive chronic epitheliopathy with a variable degree of injury. Early diagnosis can be challenging due to low prevalence, clinical suspicion, and the need for complementary diagnostic methods to confirm. New medical and surgical treatment modalities have emerged that are specifically directed to the pathophysiology of NK with promising results.
Source: Current Ophthalmology Reports - Category: Opthalmology Source Type: research

Related Links:

CONCLUSION: On the basis of a broadly based research and participatory development process, a set of indicators has been developed that enables comprehensive evaluation of the regional quality of care of cross-indication, integrated care models focusing on common diseases. In order to be able to increasingly evaluate aspects of care coordination and patient orientation, health promotion as well as nursing, palliative and emergency care in the future, it would be helpful if routine data were collected or made accessible in these areas as well. PMID: 32467041 [PubMed - as supplied by publisher]
Source: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen - Category: Health Management Tags: Z Evid Fortbild Qual Gesundhwes Source Type: research
Time for a new edition of SharpBrains’ e‑newsletter! 1. Food for (nonpartisan) Thought: Should heads of state and candidates to high office pass a cognitive/ mental fitness test? 2. A school psychologist shares good tips to support our kids and, yes, manage our own stress. Three Ss to reduce the stress of “homeschooling” our kids: Simplify, Structure, Support. 3. Wow. Mindstrong Health raises $100M to transform how we measure and promote mental health. 4. Great partnership! Kaiser Permanente offers Calm mental fitness app at no cost to millions of members. 5. “Just as you can’t self-int...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Education & Lifelong Learning Health & Wellness Technology app brain health Brain Teasers brain-teaser Calm cognitive test FDA Headsafe Kaiser-Permanente Kernel mental health mental-fitness Mindstrong Source Type: blogs
             Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS ® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).“The approval of a shorter, two-hour infusion time for OCREVUS in Europe, dosed twice yearly, will further improve the treatment experience for patients while als...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is marked by a wide range and severity of symptoms. Most patients have mild to moderate symptoms, whereas 10%–15% require hospitalization. Mortality is higher with cardiovascular disorders, diabetes, and older age.1
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: All Clinical Neurology, Viral infections, Multiple sclerosis Clinical/Scientific Notes Source Type: research
Basel, 22 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new pooled pivotal satralizumab safety results for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disorder. These data are being presented at the 6th Annual Meeting of the European Academy of Neurology (EAN) and show satralizumab was well-tolerated in a broad patient population – including adolescents, for whom there is no approved medicine. Satralizumab is an investigational humanised monoclonal antibody that targets the interleukin-6 (IL-6) receptor, believed to play a key role in the i...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
__ FDA Clears Nurocheck, Portable Device to Quickly Assess Brain Health (MS News Today): “A portable device that can quickly measure electrical activity in the brain and relay it to doctors via a smartphone app, called the Nurochek system, has been cleared by the United States Food and Drug Administration (FDA) for use as a medical device. Its developer, Headsafe, plans to it soon make this brain assessment system available for use with patients in the U.S., ages 14 and older.” The Announcement: Headsafe Announces FDA Clearance and U.S. Launch of its NUROCHEK Portable Brain Assessment System (press release): &l...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Health & Wellness Technology 510(k) clearance app brain brain health technology brain-assessment EEG electrical activity FDA Food and Drug Administration Headsafe neurological testing Nurochek portable Source Type: blogs
Autoimmune diseases such as multiple sclerosis (MS), type I diabetes (T1D), inflammatory bowel diseases (IBD), and rheumatoid arthritis (RA) are chronic, incurable, incapacitating and at times even lethal conditions. Worldwide, millions of people are affected, predominantly women, and their number is steadily increasing. Currently, autoimmune patients require lifelong immunosuppressive therapy, often accompanied by severe adverse side effects and risks. Targeting the fundamental cause of autoimmunity, which is the loss of tolerance to self- or innocuous antigens, may be achieved via various mechanisms. Recently, tolerance-...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
             Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new analyses of Phase III OPERA I and OPERA II studies, as well as the open-label extensions, showing that OCREVUS ® (ocrelizumab) treatment reduced the risk of disease and disability progression in RMS and PPMS. These new analyses add additional evidence to the benefit-risk profile of OCREVUS, including the impact of MS on people’s daily lives. The data were selected for the 72nd American Academy of Neurolog y (AAN) Annual Meeting and will be made available onlin...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Basel, 28 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1 – 7 months old with symptomatic Type 1 spinal muscular atrophy (SMA). The study met its primary endpoint with 29% of infants (12/41; p
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Analytical ChemistryDOI: 10.1021/acs.analchem.0c01115
Source: Analytical Chemistry - Category: Chemistry Authors: Source Type: research
More News: Brain | Diabetes | Endocrinology | Multiple Sclerosis | Neurology | Opthalmology